Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF

被引:1712
作者
Holash, J
Maisonpierre, PC
Compton, D
Boland, P
Alexander, CR
Zagzag, D
Yancopoulos, GD
Wiegand, SJ
机构
[1] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA
[2] NYU, Med Ctr, Kaplan Canc Ctr, Dept Pathol,Microvasc & Mol Neurooncol Lab, New York, NY 10016 USA
关键词
D O I
10.1126/science.284.5422.1994
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In contrast with the prevailing view that most tumors and metastases begin as avascular masses, evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels. This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. The expression patterns of the angiogenic antagonist angiopoietin-2 and of pro-angiogenic vascular endothelial growth factor (VEGF) suggest that these proteins may be critical regulators of this balance between vascular regression and growth.
引用
收藏
页码:1994 / 1998
页数:5
相关论文
共 41 条
[1]  
ANAKA S, 1999, J CLIN INVEST, V103, P341
[2]   Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal [J].
Benjamin, LE ;
Golijanin, D ;
Itin, A ;
Pode, D ;
Keshet, E .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :159-165
[3]   Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[4]   Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning [J].
Davis, S ;
Aldrich, TH ;
Jones, PF ;
Acheson, A ;
Compton, DL ;
Jain, V ;
Ryan, TE ;
Bruno, J ;
Radziejewski, C ;
Maisonpierre, PC ;
Yancopoulos, GD .
CELL, 1996, 87 (07) :1161-1169
[5]  
DUMONT DJ, 1992, ONCOGENE, V7, P1471
[6]   DOMINANT-NEGATIVE AND TARGETED NULL MUTATIONS IN THE ENDOTHELIAL RECEPTOR TYROSINE KINASE, TEK, REVEAL A CRITICAL ROLE IN VASCULOGENESIS OF THE EMBRYO [J].
DUMONT, DJ ;
GRADWOHL, G ;
FONG, GH ;
PURI, MC ;
GERTSENSTEIN, M ;
AUERBACH, A ;
BREITMAN, ML .
GENES & DEVELOPMENT, 1994, 8 (16) :1897-1909
[7]   Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia [J].
Enholm, B ;
Paavonen, K ;
Ristimaki, A ;
Kumar, V ;
Gunji, Y ;
Klefstrom, J ;
Kivinen, L ;
Laiho, M ;
Olofsson, B ;
Joukov, V ;
Eriksson, U ;
Alitalo, K .
ONCOGENE, 1997, 14 (20) :2475-2483
[8]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442
[9]  
Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
[10]  
FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182